Clinical Trial Update: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial updates the use of durvalumab (MEDI4736) in combinations for metastatic renal cell carcinoma, with the study now completed. Conditions include ren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Queen Mary University of London | Conditions: Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma | Phase 2 | Status: COMPLETED